Orthobiologics company gets clearance for bone marrow aspirate system

Royal Biologics received FDA approval for its MAXX-BMC bone marrow aspirate concentration system.

Advertisement

The system is the latest addition to the company’s portfolio of advanced cellular technologies and enhanced autologous healing solutions, according to a June 1 news release. Its lead screw technology is designed to create a customized sample point of care for use during orthopedic and sports medicine surgical procedures.

Royal Biologics’ regenerative medicine portfolio includes platelet-rich plasma and bone marrow products.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in Biologics

Advertisement

Comments are closed.